Pricing Log in Create free account
Friday 6 November 2026 Export TDOC’s income statement to Excel — free account

Teladoc Health, Inc.

TDOC Healthcare Health Information Services

Teladoc Health, Inc.’s revenue for fiscal 2025 (year ended December 2025) was $2.5 billion, down 1.54% from fiscal 2024.

Revenue
−3.41%
EPS
+47.1%
Free cash flow
+11.8%
Total debt
+0.36%

Quarter to September 2026, against a year earlier

8.84 0.57 −6.06%
Market cap
$1.7B
P/E
0.0×
Fwd P/E
−10.1×
Dividend yield
—
F-score
5/9
Altman Z
−6.66
Beneish M
−3.26
Dividend safety
n/a
Overview
Financials
Income Statement Balance Sheet Cash Flow Metrics & Ratios

Insider Decisions last twelve months

Sold, $m 2.07
Trades a month
Jan 26 Apr 26 Jul 26 Oct 26
Buy — — — — — — — — — — — —
Sell 5 1 — 5 1 — 9 3 — 7 1 —
Insider Ownership 0.50%

Capital & Financial Ratios $m

Size
Market Cap 1,720.00
Revenue ttm 2,468.14
Net income ttm (154.82)
Free cash flow ttm 126.12
Net debt Q 147.68
Valuation
P/E 0.00
Forward P/E (10.10) (negative: loss-making)
Price / sales 0.70
Forward P/S Powerpack
Price / FCF 13.61
Price / book 1.33
Financial health
Current ratio Q 0.87 (below 1: weak)
Debt / equity Q 0.77
Interest coverage Q (5.69)
Growth
Revenue growth Q −3.41% (below 0%: shrinking)
Operating income growth Q +45.92% (above 0%: growing)
EPS, this year +26.27% (at or above 15%: strong)
EPS, next year A +26.80% (at or above 15%: strong)
Revenue, next year A −4.51% (below 0%: weak)
EPS, past 5 yrs —
EPS, next 5 yrs A +21.44% (at or above 15%: strong)

Green and red mark values outside typical ranges; (Q) is the latest quarter, (A) analysts’ estimates. How we judge →

Valuation vs history

EV/Sales, ten years
EV/Sales is 1.2×, against a ten-year median of 6.2×; over the ten years it ranged from 0.6× in 2025 to 24.9× in 2020.
P/S against its own 10 years 20.94%
10-year low 10-year high
P/B against its own 10 years 38.32%
10-year low 10-year high
EV/Sales against its own 10 years 24.64%
10-year low 10-year high
EV/FCF against its own 10 years 26.38%
10-year low 10-year high

Dividends

Yield
—
Annual rate
—
Payout ratio
—

Assets vs Liabilities $m

2023 2024 2025 Q'26
Cash 1,124 1,298 781 850
Receivables 217 214 193 231
Inventory 30 38 38 31
Other — — — —
1,489 1,664 1,119 1,226
2023 2024 2025 Q'26
Payables 44 33 48 46
ST’ Debt — 551 — 998
Other — — — —
421 942 405 1,416

Compound Annual Growth %

10y 5y 3y
Sales 41.73% 18.26% 1.68%
Cash Flow 0.00% 0.00% 15.85%
Earnings 0.00% 0.00% 0.00%
Book Value 22.74% (38.60%) (15.64%)

Earnings Trends EPS, adjusted, against the consensus

Q3 FY26 Estimate −0.23 Actual −0.15

Earnings per share against the consensus, by quarter
Quarter Estimate Reported Result
Q4 FY25 −0.19 −0.14 Beat by 0.05
Q1 FY26 −0.32 −0.36 Miss by 0.04
Q2 FY26 −0.24 −0.21 Beat by 0.03
Q3 FY26 −0.23 −0.15 Beat by 0.08
Q4 FY26 −0.11 — Reports 24 February 2027

EPS $

Mar Jun Sep Dec Year
’26 (0.36) (0.21) (0.15) — —
’25 (0.53) (0.19) (0.28) (0.14) (1.14)
’24 (0.49) (4.92) (0.19) (0.28) (5.87)
’23 (0.42) (0.40) (0.35) (0.17) (1.34)
’22 (41.58) (19.22) (0.45) (23.49) (84.60)
’21 (1.31) (0.86) (0.53) (0.07) (2.73)
’20 (0.40) (0.34) (0.43) (4.19) (5.36)
Fiscal quarters ending in the months shown.

Revenue $m

Mar Jun Sep Dec Year
’26 614 607 605 — —
’25 629 632 626 642 2,530
’24 646 642 641 640 2,570
’23 629 652 660 661 2,602
’22 565 592 611 638 2,407
’21 454 503 522 554 2,033
’20 181 241 289 383 1,094
Fiscal quarters ending in the months shown.

Operating Cash Flow $m

Mar Jun Sep Dec Year
’26 10 65 106 — —
’25 16 91 99 88 294
’24 9 89 110 86 294
’23 13 101 106 130 350
’22 (32) 92 63 66 189
’21 (18) 52 77 83 194
’20 (6) 36 32 (115) (54)
Fiscal quarters ending in the months shown.

Free Cash Flow $m

Mar Jun Sep Dec Year
’26 (26) 23 76 — —
’25 (16) 32 68 53 137
’24 (27) 61 79 56 170
’23 (76) 30 36 94 194
’22 (89) 5 (20) (36) (140)
’21 (42) 29 48 40 75
’20 (11) 26 15 (131) (102)
Fiscal quarters ending in the months shown.

Target Price Range

Analyst price targets

Recommendation Rating

2.6
1Buy 2 3Hold 4 5Sell

Ten years at a glance Fiscal years to December

Ten-year view Analyst estimates Powerpack
Group Line 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 TTM Sep ’26 Trend 10 yrs 2026e 2027e 2028e Next 3/yr
Income, $m
Income, $m Revenue 123 233 418 553 1,094 2,033 2,407 2,602 2,570 2,530 2,468 +39.9% 2,416 2,363 2,387 (1.9%)
Gross margin, % 74.04 73.58 69.20 66.66 64.27 68.01 69.09 70.80 70.76 69.50 68.57 (4.5) pt
EBT (74) (107) (97) (109) (576) (385) (13,663) (220) (994) (236) (159) +13.8%
EBT margin, % (59.85) (45.87) (23.20) (19.78) (52.65) (18.92) (567.69) (8.44) (38.67) (9.31) (6.43) +50.5 pt
Net income (74) (107) (97) (99) (485) (429) (13,660) (220) (1,001) (200) (155) +11.7%
Per share, $
Per share, $ Revenue 2.91 4.21 6.35 7.70 12.09 12.95 14.91 15.81 15.07 14.36 13.57 +19.4%
Earnings (1.75) (1.93) (1.47) (1.38) (5.36) (2.73) (84.60) (1.34) (5.87) (1.14) (0.86) (4.7%)
Cash flow (1.23) (0.62) (0.07) 0.42 (0.59) 1.24 1.17 2.13 1.72 1.67 1.48 n/m
Capex (0.11) (0.15) (0.11) (0.25) (0.53) (0.76) (2.04) (0.95) (0.73) (0.89) (0.78) +26.0%
Free cash flow (1.34) (0.77) (0.18) 0.16 (1.12) 0.48 (0.87) 1.18 0.99 0.78 0.69 n/m
Book value 5.45 10.08 15.39 14.11 175.49 102.24 14.29 14.13 8.74 7.86 7.12 +4.1%
Shares, m 42 55 66 72 91 157 161 165 171 176 180 +17.2%
Valuation, ×
Valuation, × P/E 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.0
P/S 5.67 8.60 7.81 10.87 16.54 7.09 1.51 1.39 0.60 0.49 0.70 6.1
P/B 3.03 3.59 3.22 5.93 1.14 0.90 1.58 1.55 1.04 0.89 1.33 2.3
EV/Sales 5.50 8.97 7.66 10.74 17.12 7.26 1.78 1.55 0.70 0.79 1.16 6.2
EV/FCF (11.96) (48.87) (263.92) 513.27 (184.44) 197.61 (30.60) 111.48 29.98 14.55 22.68 32.7
Cash, $m
Cash, $m Operating cash flow (52) (34) (5) 30 (54) 194 189 350 294 294 268 n/m
Capex (5) (8) (7) (18) (48) (119) (329) (156) (124) (157) (142) +47.6%
Free cash flow (57) (43) (12) 12 (102) 75 (140) 194 170 137 126 n/m
Balance, $m
Balance, $m Working capital 62 116 470 498 727 894 916 1,068 722 714 (189) +31.3%
Net debt (21) 85 (64) (72) 636 343 631 415 244 214 148 n/m
Shareholders’ equity 231 559 1,013 1,014 15,884 16,046 2,308 2,326 1,491 1,386 1,295 +22.0%
Returns, %
Returns, % ROA (27.83) (18.93) (8.25) (6.31) (5.01) (2.42) (123.73) (5.04) (25.32) (6.28) (5.48) +21.6 pt
ROIC (18.70) (7.32) (4.67) (5.34) (1.92) (1.01) (290.36) (5.67) (36.78) (10.27) (7.06) +8.4 pt
ROE (36.25) (27.04) (12.35) (9.75) (5.74) (2.69) (148.85) (9.51) (52.46) (13.93) (11.52) +22.3 pt
People
People Employees 670 1,231 2,000 2,400 4,400 5,100 5,600 5,600 5,500 5,600 — +26.6%
Revenue/emp, $m 0.18 0.19 0.21 0.23 0.25 0.40 0.43 0.46 0.47 0.45 — +10.5%
Negative figures in brackets.
estimates

All 10 years →

Fiscal years to Dec 2025 · latest quarter Sep 2026 · fundamentals updated 2 Nov 2026

Teladoc Health, Inc. vs peers in Health Information Services (Q) = latest quarter vs a year earlier

Company Market cap P/E Fwd P/E Revenue growth (Q) EPS growth (Q) FCF growth (Q) Gross margin (Q) EBIT margin (Q) Compare
PRVA Privia Health Group, Inc. $3.1B 88.3× 83.4× +13.19% (above 0%: growing) +83.33% (above 0%: growing) −44.35% (below 0%: shrinking) 0.00% 3.13% Compare
SDGR Schrodinger, Inc. $2.2B — (loss-making) — (loss-making) +18.72% (above 0%: growing) n/m +21.64% (above 0%: growing) 59.32% (40.52%) Compare
CERT Certara, Inc. $1.9B — (loss-making) — (loss-making) −9.29% (below 0%: shrinking) +300.00% (above 0%: growing) −12.09% (below 0%: shrinking) 66.87% 2.45% Compare
OMCL Omnicell, Inc. $1.7B 39.0× 32.9× −0.89% (below 0%: shrinking) +100.50% (above 0%: growing) +42.62% (above 0%: growing) 44.77% 4.85% Compare
TDOC Teladoc Health, Inc. $1.7B — (loss-making) — (loss-making) −3.41% (below 0%: shrinking) n/m +11.76% (above 0%: growing) 68.56% (4.64%)
GDRX GoodRx Holdings, Inc. $1.2B 65.7× 46.0× −1.31% (below 0%: shrinking) −25.00% (below 0%: shrinking) +112.45% (above 0%: growing) 89.52% 11.79% Compare
OMDA Omada Health, Inc. $1.2B 267× 156× +43.12% (above 0%: growing) n/m +45.71% (above 0%: growing) 72.62% 4.04% Compare
HSTM HealthStream, Inc. $905.6M 42.0× 45.4× +8.94% (above 0%: growing) −8.90% (below 0%: shrinking) −4.80% (below 0%: shrinking) 63.98% 7.91% Compare
PHR Phreesia, Inc. $788.9M 74.4× 40.2× +10.41% (above 0%: growing) +200.00% (above 0%: growing) +43.51% (above 0%: growing) 66.64% 5.88% Compare
Median of peers $1.5B 70.0× 45.7× +9.68% +91.91% +32.13% 65.31% 4.45%

All 44 Health Information Services stocks →

Pay and ownership Proxy statement filed 7 April 2026

Ownership

Directors and executive officers, together 0.70%
Ownership is the proxy’s own table: the directors and officers as a group, and every holder of 5% or more. Read the proxy statement

Teladoc Health, Inc. (TDOC) Latest News

6 Nov

Impact 3 · · Simply Wall St.

2 Nov

Impact 3 · · StockStory

31 Oct

Impact 3 · · StockStory

29 Oct

Impact 4 · · Simply Wall St.
Impact 4 · · TIKR
Impact 4 · · MarketBeat
Impact 4 · · The Motley Fool
Impact 4 · · The Motley Fool transcript
Impact 3 · · StockStory
Impact 3 · · Moby

28 Oct

Impact 4 · · StockStory
Impact 4 · · GlobeNewswire
Impact 3 · · Zacks
Impact 3 · · Zacks

27 Oct

Impact 3 · · Simply Wall St.
Impact 3 · · StockStory
Impact 3 · · Zacks

19 Oct

Impact 3 · · Zacks

13 Oct

Impact 3 · · Zacks

9 Oct

Impact 3 · · Simply Wall St.

8 Oct

Impact 4 · · Zacks

7 Oct

Impact 4 · · Benzinga
Impact 4 · · healthcaredive.com
Impact 3 · · Simply Wall St.
Impact 3 · · GlobeNewswire

29 Sep

Impact 3 · · Zacks

25 Sep

Impact 3 · · GlobeNewswire

23 Sep

Impact 3 · · Zacks

18 Sep

Impact 4 ·

7 Sep

Impact 3 ·
stockrow.com/TDOC · Data as of Nov 2, 2026 · For information only; not investment advice. · © 2026 stockrow.com